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ABSTRAK
Tujuan: mempelajari kejadian perpanjangan interval QTc pada pemakaian amiodaron di RSCM dan 
faktor yang mempengaruhinya. Metode: penelitian deskriptif retrospektif dilakukan berdasarkan rekam medik 
pasien yang dirawat di ICCU RSCM tahun 2004-2011. Penelitian dilakukan pada 4 kelompok pasien yaitu 
(1) kelompok yang menggunakan amiodaron dan obat lain yang menyebabkan perpanjangan interval QTc; 
(2) kelompok yang menggunakan amiodaron dengan obat-obat lain yang tidak menyebabkan perpanjangan 
interval QTc; (3) kelompok yang menggunakan obat selain amiodaron yang memperpanjang interval QTc 
dan (4) kelompok kontrol (tidak menggunakan amiodaron atau obat lain yang memperpanjang interval QTc). 
Perubahan interval QTc (DQTc) selama perawatan dalam satu kelompok dianalisis dengan uji t berpasangan 
atau Wilcoxon. Perbandingan DQTc antar kelompok dianalisis dengan uji Kruskal Wallis. Pengaruh faktor 
lain (jenis kelamin, umur, gagal jantung, fungsi hati dan elektrolit) terhadap kejadian perpanjangan interval 
QTc dianalisis dengan menggunakan regresi multipel. Hasil: perpanjangan interval QTc pada kelompok 1, 2, 
dan 3 secara berturut-turut adalah 65,5%, 63,3%, 56,6% yang berbeda bermakna dibandingkan kelompok 
kontrol (24,4%, p <0,05). Tidak terdapat potensiasi perpanjangan interval QTc bila amiodaron dikombinasi 
dengan obat lain yang menyebabkan perpanjangan QT. Hipernatremia dan hipertensi merupakan faktor risiko 
terjadinya perpanjangan interval QTc. Terdapat kematian pada kelompok 1, 2, dan 3 masing-masing 3, 4, dan 
4 pasien, sedangkan pada kelompok 4 tidak terdapat kematian. Kesimpulan: perpanjangan interval QTc secara 
bermakna terjadi pada pemakaian amiodaron dan beberapa obat yang menyebabkan perpanjangan interval QT, 
namun tidak terjadi potensiasi bila kedua kelompok obat digunakan bersamaan. Hipernatremia dan hipertensi 
memberikan kontribusi pada perpanjangan interval QTc.
Kata kunci: amiodaron, anti-aritmia, interval QTc.
ABSTRACT
Aim: to evaluate the incidence of QTc interval prolongation associated with the use of amiodarone, as well 
as factors that influence its occurrence. Methods: this was a descriptive retrospective study conducted from 
November 2010 until December 2011 using medical record of patients at ICCU Cipto Mangunkusumo Hospital 
from 2004-2011. Four groups of patients were included: (1) patients receiving amiodarone and other drugs 
causing which can cause QTc prolongation, (2) patients receiving amiodarone and other drug not causing  QTc 
prolongation, (3) patients receiving drugs which can cause causing QTc prolongation, (4) patients not receiving 
amiodarone, nor other drugs which can cause causing  QTc prolongation (served as control group). Difference 
of QTc interval within the same group was analyzed with paired t-test or Wilcoxon matched-pairs test. Between 
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groups comparison were performed with Kruskal Wallis test. The influence of other factors (sex, age, heart 
failure, liver disorder, electrolyte imbalance) on QTc prolongation was analyzed using multiple regression. 
Results: QTc interval prolongation in groups 1, 2, and 3 were respectively 65.5%, 63.3%, 56.6%, which were 
significantly different from control group (24.4%); Hypernatremia and hypertension were revealed as significant 
risk factor for QTc prolongation. Mortality occurred in 3, 4, and 4 patients in group 1, 2, and 3 respectively, and 
none in group 4. Conclusion: QTc interval prolongation occurred in association with amiodarone and other 
drugs known to prolong QTc interval. Hypernatremia and hypertension were shown as significant influencing 
factor of QTc interval prolongation.
Key words: amiodarone, antiarrhythmia, QTc interval.
INTRODUCTION
A m i o d a r o n e  i s  a  w i d e  s p e c t r u m 
antiarrhythmic drug which shows very good 
activity against various types of arrhythmias 
including atrial flutter and fibrillation, as well 
as arrhythmias of ventricular origin. It has a 
good pharmacologic profile, and represents 
the most widely used antiarrhythmia.1 Beside 
its good pharmacologic profile, amiodarone 
possesses a potentially dangerous adverse effect, 
i.e QT interval prolongation which can lead to 
torsade des pointes or polymorphic ventricular 
arrhythmia, which may end with ventricular 
fibrillation and sudden death.2,3
QT interval is defined as the time needed by 
the ventricle to perform complete depolarization 
and repolarization.1,2 Some drugs are known to 
induce QT interval prolongation by inhibiting 
outward current of potassium ion, which lead 
to prolongation of myocardial repolarization. 
Some drugs in the group of antiarrhythmic 
drugs, antidepressants, antipsychotics such 
as haloperidol, and some antibiotics such as 
quinolones, azithromycin, and metronidazole, 
are known to cause QT interval prolongation.4-6
Some patients admitted to intensive cardiac 
care unit known to have various types of 
arrhythmia and need antiarrhythmic drugs, 
including amiodarone. Some of them also 
received concomitant drugs causing QT interval 
prolongation. However, publication on the 
incidence of QT interval prolongation in this 
group of patients in Indonesia is still lacking. 
In the present study, we aimed to evaluate 
the incidence of QTc interval prolongation in 
patients receiving amiodarone and other drugs 
which can cause QT prolongation at Intensive 
Cardiac Care Unit of Cipto Mangunkusumo 
Hospital, Jakarta. Role of other factors such as 
gender, electrolyte imbalance, presence of heart 
failure and liver disorder in the occurrence of QT 
interval prolongation was also evaluated.
METHODS
This was a descriptive retrospective 
study conducted using secondary data from 
medical record of patients hospitalized in the 
Intensive Cardiac Care Unit (ICCU) of Cipto 
Mangunkusumo Hospital, Jakarta during the 
period of 2004 to 2011. All patients aged between 
16-65 years were included in this study, while 
those with incomplete or unreadable ECG data 
were excluded. A total of 200 samples were 
planned, but only 176 samples were eligible for 
analysis. The protocol of this study has been 
approved by Research Ethics Committee of the 
Faculty of Medicine Universitas Indonesia.
The patients were classified into 4 groups 
according to the drugs they received. Group I 
received amiodarone and other drugs causing 
QT prolongation; group II received amodarone 
and other drug(s) not causing QT prolongation; 
group III received other drugs causing QT 
prolongation, without amiodarone; and group IV 
received neither amiodarone, nor drugs causing 
QT prolongation. Since QT interval is inversely 
correlated with heart rate, thus, it is presented 
as corrected QT interval (QTc). The correction 
formula used in this study is based on Bazett 
equation where QTc = QT/(RR).7
During this study, QT interval prolongation is 
defined as QTc more than 450 ms, or the increase 
of more than 30% from baseline value, and lead II 
was taken as reference of QT interval calculation.6
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Data Analysis
Demographic data as well as laboratory 
results were reported descriptively. The difference 
of QTc interval (DQTc) between baseline and 
the longest QTc during hospitalization within 
one group was analyzed by using paired t-test 
or Wilcoxon matched-pair test. Percentage of 
difference between groups were analyzed by 
using Kruskal Wallis test. Influence of other 
factors such as gender, age, presence of heart 
failure, serum electrolyte on QT prolongation was 
analyzed by multiple regression with backward 
approach. Mortality in each group was presented 
descriptively.
RESULTS
A total of 176 data have been collected 
comprising of group I (29 patients), II (49 
patients), III (53 patients), and IV (45 patients). 
Table 1 shows distribution of patients according 
to gender, age, cardiac diseases, serum electrolyte, 
and liver function.




n (%)I II III IV
n (%) n (%) n (%) n (%)
Gender:
 - Male 20 (69) 33 (67) 33 (62) 28 (62) 114 (65)
 - Female 9 (31) 16 (33) 20 (38) 17 (38) 62 (35)
Age:
 - Years (SD) 58 (10) 51 (12) 53 (7) 52 (7) 53 (9)
 - Range 30 - 69 25 - 69 32-65 36-65 25-69
Cardiac disease:
 - UAP 2 (6,8) 8 (16,3) 14 (26,4) 10 (22,2) 34 (19,3)
 - NSTEMI 9 (31) 6 (12,2) 17 (32) 15 (33,3) 47 (26,7)
 - STEMI 11 (37,9) 18 (36,7) 16 (30,2) 15 (33,3) 60 (34,1)
Heart failure:
 - Yes 18 (62) 23 (47) 31 (58) 9 (20) 81 (46)
 - No 11 (38) 26 (53) 22 (42) 36 (80) 95 (54)
Serum electrolyte:
 - Hypokalemia 5 (17.2) 5 (9.4) 14 (26.34) 4 (8.9) 28 (15.9)
 - Normokalemia 23 (79.3) 40 (81.6) 37 (69.8) 39 (86.7) 139 (78.9)
 - Hypernatremia 5 (17.2) 7 (13.2) 6 (11.3) 4 (8.9) 22 (12.5)
 - Normonatremia 23 (79.3) 40 (75.5) 45 (84.9) 38 (54.4) 146 (82.9)
Liver function:
 - High SGPT 3 (10.3) 5 (10.2) 5 (9.4) 5 (11.1) 18 (10.2)
 - Normo SGPT 21 (72.4) 35 (71.4) 38 (71.6) 32 (71.1) 126 (71.6)
HF : heart failure, UAP: unstable angina pectoris, NSTEMI: non ST-elevated myocardial infarction, STEMI: ST elevated 
myocardial infarction
Table 2 shows baseline QTc interval and 
prolonged QTc interval of subjects in all groups. 
A significant increase of QTc interval can be seen 
in all group. However, the first three groups has 
about the same magnitude of QTc prolongation, 
while the group IV which did not received neither 
amiodarone, nor drug causing prolonged QT, 
showed a significantly lower QTc prolongation. 
(Figure 1)
Beside the magnitude of QTc prolongation, it 
can be seen that the proportion of patients having 
QTc interval prolongation was also significantly 
lower in group IV (Table 3).
Table 4 shows that azithromycin was the 
most frequent drug causing prolonged QT 
received by the subjects. QTc prolongation was 
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slightly less in group receiving azithromycin 
compared with amiodarone or combination of 
amiodarone and azithromycin, but this different 
was not significant. Other drugs (metronidazole 
and haloperidol) are used in much less frequency.
Table 2. Comparison of baseline and prolonged values of 





Group I 434.8 (57.1) 478.4 (81.5) 0.001
Group II 446.9 (72.4) 497.6 (108.7) 0.008
Group III 464.8 (75.2) 515.40 (71.7) 0.001
Group IV 454.3 (51.1) 468.4 (55.4) 0.008
Tabel 3. Proportion of patients experiencing QTc interval 




n (%) Total N
Group I 19 (65.5) 10 (34.5) 29
Group II 31 (63.3) 18 (36.7) 49
Group III 30 (56.6) 23 (43.4) 53
Group IV 11 (24.4)* 34 (75.6) 45
Total 91 (51.7) 85 (48.3) 176
* p<0.05 vs group I, II, III
Figure 1. Magnitude of changes of QTc interval in all groups 
during hospitalization at the ICCU
Table 4. Influence of concomitant drug(s) on the 
occurrence of QTc prolongation
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Influence of Some Risks Factors on the 
Occurrence of QTc Prolongation
Result of multiple regression shows that 
among several factors dialyzed, hypernatremia, 
lung disease, and hypertension have significant 
influence on the occurrence of QTc interval 
prolongation (Table 5).
Tabel 5. Multiple regression of the influence of risks factors 
on the occurrence of QTc interval prolongation
Risk factors B (slope) p
Gender 0,040 0.911
Heart failure 0,201 0.569
Hypokalemia -0,321 0.490
Liver disease 0,358 0.488
Hypernatremia 1,264 0.019
Arrhytmia -0,034 0,928
Lung disease -0,644 0,039
Hypertension 0,830 0,009
DISCUSSION
Amiodarone  be longs  to  c l a s s  I I I 
antiarrhythmic drugs which shares the property 
of all other classes of antiarrhythmic drugs. 
This drug is considered the most frequently 
used antiarrhythmic agent owing to its broad 
spectrum of action that make it effective in many 
types of arrhythmias. On one hand, it has a good 
clinical profile, with relatively low incidence of 
adverse effects if used by respecting specific 
prcautions and contraindications such as liver 









I II III IV
groups
* p<0.05 vs. gr I, II, III
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also has the potential of inducing arrhythmias, 
one of which is QT interval prolongation that 
can lead to serious polymorphic ventricular 
arrhythmia or torsade de pointes (TdP).8 This 
type of arrhythmia is related to the mechanisms 
of action of amiodarone by blocking potassium 
channel and causes prolongation of ventricular 
repolarization and the refractory period, -leading 
to QT-interval prolongation.9
Beside amiodarone, some other drugs are 
also reported to have the potential to cause QT 
prolongation, such as azythromycin, haloperidol, 
metronidazole, cisapride, erythromyin, clozapine, 
etc. Adverse Drug Reaction Advisory Committee 
(ADRAC 2005) of Australia,10 reported 140 
cases of QTc prolongation and/or torsade de 
pointes. Seven of them were fatal. The most 
frequently implicated drugs in these reports are 
sotalol, cisapride, clozapine, amiodarone and 
erythromycin.
In the present study, we found significant 
frequent of QT interval prolongation in the group 
receiving amiodarone or other drug causing QT 
prolongation, either alone or in combination. It 
is interesting to note, that there was no further 
potentiation of QT interval prolongation if 
amiodarone was used in combination with other 
QT prolongation inducer drugs. This finding is 
different from that of Samarendra et al,11 who 
reported the potentiation of QT prolongation if 
two groups of drugs are combined.  Explanation 
of this different result is not clear, but it might 
be due to the influence of different cadiovascular 
background and the small sample size.
Azithromycin is a macrolide antibiotic that 
frequently used to treat pneumonia. It is known 
that patients with severe clinical conditions are 
prone to contract nosocomial infection or hospital 
associated pneumonia in which combination of 
antibiotics is recommended. However, in the 
last several years, some reports emerged on 
the increase of QT prolongation associated 
with azythromycin.12-14 In the present study, 
azithromycin is the most frequent drug causing 
QT prolongation used by the patients, and most 
of them experienced QT interval prolongation. 
This finding is consistent with a cohort study 
conducted by Ray et al. on more than three 
hundreds patients taking azithromycin.15 The 
authors found that the risk of cardiovascular 
death was significantly higher in patients 
taking azithromycin compared to those taking 
amoxicillin, or those taking no antibiotic, but 
comparable with levofloxacin.16
Besides concomitant drugs, we have also 
evaluated some other influencing factors 
of QT prolongation. Among these factors, 
hypernatremia, lung disease, and hypertension 
were found to have significant influence on the 
occurrence of QT interval prolongation. Other 
study by Moreno et al.,16 (2011) also reported that 
hypernatremia was associated with QT interval 
prolongation, while gender, serum potassium 
level, and liver or kidney function did not show 
significant influence.
On theorethical point of view, hypokalemia 
can induce arrhythmia, since low extracellular 
potassium level decreases IKr,4 an effect that is 
likely to contribute to QT interval prolongation. 
However, in this study, as well as in that of 
Moreno,16 hypokalemia was not related with QT 
prolongation. On the contrary, some literatures 
reported that hypokalemia is an important risk 
factor of TdP development.4,6 Explanation of 
this contradictory findings of hypokalemia 
and hypernatremia on the occurrence of QT 
prolongation is not well understood. The fact is 
sodium and potassium ions compete for access 
to extracellular binding sites on IKr channel and 
sodium is a potent blocker of this current. It can 
be speculated this competition might explain the 
occurrence of QTc prolongation in this study.
Concerning the influence of gender, Stramba-
Badiale et al., (1997) reported that female gender 
may play determinant role in the occurrence of 
QT interval prolongation.17 It is suggested that 
sex steroid hormones may have differential 
influences on ventricular repolarization, since 
the tendency of prolonged QT interval in female 
is only observed after puberty.
Concerning mortality, we observed mortality 
in groups receiving amiodarone or other drugs 
causing prolonged QT, alone or in combination. 
Among all mortalities, 3 was caused by sudden 
cardiac death, 4 due to cardiogenic shock, 
and others were due to pneumonia and septic 
shock. The role of QT interval prolongation in 
these mortalities could not be concluded, since 
Vol 46 • Number 4 • October 2014                                   QT interval prolongation associated with amiodarone use
297
it occurred shortly after hospital admission. 
Thus, the severe heart attack seemed to be more 
possible as the cause of death.
In this study, no cases of severe arrhythmia, 
such as torsade des pointes, was observed. 
Indeed, amiodarone frequently prolonged QT 
interval, but the incidence of torsade de pointes 
was reported to be low.6 With small sample size 
in our study, the probability to find the TdP was 
thus very low.
CONCLUSION
From this study, we concluded that the use 
of amiodarone in Cipto Mangunkusumo Hospital 
was associated with a high incidence of QT 
interval prolongation, but no serious arrhythmia 
was observed. The use of other drugs causing 
QT prolongation resulted in similar incidence 
of QT interval prolongation. No potentiation 
effect was found when these two drugs were used 
in combination. Hypernatremia was shown as 
contributing factor to QTc interval prolongation. 
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